The interplay between pulmonary arterial hypertension (PAH) and tricuspid regurgitation (TR) represents one of the most complex hemodynamic relationships in modern cardiovascular medicine. Traditionally, the coexistence of severe PAH and significant TR has been perceived as a near-impenetrable therapeutic barrier, simultaneously reflecting advanced right ventricular (RV) failure and signaling a markedly poor prognosis. Surgical intervention on the tricuspid valve has historically been contraindicated in these patients due to prohibitive perioperative risk and the high likelihood of postoperative RV decompensation. Yet contemporary transcatheter therapies, combined with optimized PAH-specific pharmacologic regimens, have begun to challenge these long-standing assumptions.
The case described in the provided clinical report offers an instructive example of how advanced medical therapy—particularly targeted PAH therapy with agents such as macitentan and tadalafil—can sufficiently restore RV–pulmonary artery (PA) coupling to allow successful transcatheter tricuspid valve repair (TTVR). This transformation is not merely mechanical; it represents a complex reversal of maladaptive hemodynamics, an alignment of cardiac and pulmonary physiology, and a strategic staging of interventions that redefines how clinicians should conceptualize high-risk TR in the setting of PAH.
This article presents a detailed academic dissection of that case, focusing on pathophysiological mechanisms, diagnostic considerations, hemodynamic interpretation, therapeutic sequencing, and outcome analysis. It is written with the precision expected of senior academic clinicians, grounded entirely in the evidence and details provided in the case report.
Pathophysiological Framework: Understanding TR in the Setting of Advanced Pulmonary Arterial Hypertension
The coexistence of PAH and TR is not incidental. Chronic pressure overload imposed on the right ventricle by elevated pulmonary vascular resistance (PVR) induces progressive RV hypertrophy, dilation, and eventual geometric distortion of the tricuspid annulus. Functional tricuspid regurgitation arises when annular dilation and leaflet tethering prevent adequate coaptation. As TR worsens, forward stroke volume falls, systemic venous pressure rises, and low-output symptoms emerge.
In PAH, the sequence is self-reinforcing. TR increases RV volume overload, which exacerbates RV dilation, further stretching the annulus and worsening regurgitation. This vicious circle produces a downward spiral recognizable to all cardiologists who manage right-sided pathology. In advanced cases, TR is both a marker and a mechanism of failing RV–PA coupling—a concept that reflects the ability of the RV to adapt its contractility to afterload.
The patient in the case exhibited this classic phenotype: severe PAH with high pulmonary arterial pressures, accompanied by severe TR and clear signs of RV dysfunction. At presentation, the RV was unable to generate sufficient contractile reserve to counteract afterload, resulting in poor forward flow and symptomatic limitation. Without intervention, such patients often progress rapidly to advanced congestion, arrhythmia, and multiorgan dysfunction.
However, a crucial detail in this case is that PAH-specific therapy was not maximal at baseline. This distinction opens a mechanistic door: if targeted vasodilator therapy can significantly reduce PVR, RV contractility may once again align with afterload demands, restoring RV–PA coupling and potentially reversing functional TR.
Pharmacologic Optimization: Restoring RV–PA Coupling Before Valve Intervention
The decision to initiate or intensify PAH-specific therapy before addressing TR represents a cornerstone of modern right-heart management. In this case, the combination of macitentan, an endothelin receptor antagonist, and tadalafil, a phosphodiesterase-5 inhibitor, was implemented as guideline-supported therapy for WHO Group 1 PAH.
The physiological effects of these medications reach beyond mere vasodilation. Endothelin blockade reduces pulmonary vascular remodeling, while PDE5 inhibition enhances nitric oxide–mediated signaling, improving vasodilation, RV perfusion, and RV contractile reserve. Together, these agents have been shown to reduce PVR, improve right-sided hemodynamics, and enhance exercise capacity.
In the patient described, medical therapy produced measurable improvements: pulmonary pressures decreased, RV function stabilized, and the patient’s symptomatic status improved. Most critically, imaging demonstrated improved RV geometry and contractility — prerequisites for any valve intervention in severe PAH. Without adequate RV recovery, TTVR could precipitate catastrophic hemodynamic collapse by suddenly increasing RV afterload.
The timing and magnitude of response to PAH therapy demonstrate a crucial pathophysiological principle: functional TR in the setting of PAH is often partially reversible when RV–PA coupling is restored, and any interventional approach must wait until pharmacotherapy achieves maximal hemodynamic benefit.
Clinical Imaging and Hemodynamic Assessment: Identifying Candidacy for Transcatheter Repair
One of the defining aspects of the case is the careful application of multimodality imaging to determine whether the patient could safely undergo TTVR. Transthoracic echocardiography (TTE) revealed severe TR with large coaptation gaps and annular dilation—features consistent with advanced functional TR. However, repeat imaging following PAH therapy showed substantial improvement in RV performance, as evidenced by increased TAPSE (tricuspid annular plane systolic excursion), improved RV fractional area change, and more favorable sPAP estimates.
Right-heart catheterization (RHC), the gold standard for assessing PVR, confirmed the reduction in pulmonary vascular load. The hemodynamics suggested that the RV had regained sufficient contractile reserve to tolerate changes in loading conditions associated with tricuspid repair.
These improvements are not trivial. TTVR artificially reduces regurgitant volume, increasing RV afterload. In patients with uncoupled RV–PA physiology, this leads to abrupt RV failure. Thus, verified hemodynamic stability is mandatory before proceeding to TTVR, and in this case, optimization succeeded in turning a previously nonviable candidate into an appropriate procedural candidate.
The rigorous preprocedural evaluation illustrates a clinical principle: TR intervention should be considered not in isolation but as a component of integrated right-heart management. The case report captures this interplay elegantly.
Procedural Considerations: Executing Transcatheter Tricuspid Valve Repair in a High-Risk Hemodynamic Profile
The patient underwent transcatheter tricuspid valve repair—specifically, edge-to-edge leaflet approximation using a system analogous to MitraClip but adapted for tricuspid anatomy. Even with optimized hemodynamics, the procedure remains technically demanding. The tricuspid valve’s complex geometry, wide annulus, and variable leaflet anatomy present unique challenges. Moreover, in PAH patients with dilated right atria and distorted annular geometry, precise leaflet grasping requires careful imaging guidance and operator expertise.
The procedure described achieved successful leaflet approximation, resulting in a significant reduction in TR severity. Procedural success is defined not merely by immediate reduction in regurgitant jet but by achieving durable leaflet capture, restoration of coaptation, and avoidance of procedural complications such as leaflet injury, device detachments, or chordal entanglement.
Hemodynamic tolerance during the procedure further confirmed that RV–PA coupling had been sufficiently restored by pharmacologic therapy. The patient tolerated the post-procedural increase in forward stroke volume without evidence of acute RV decompensation, a testament to successful staging of interventions.
The role of TTVR in PAH remains controversial, but this case demonstrates that carefully selected patients—those in whom RV function has been partially restored—can undergo TTVR safely and effectively.
Post-Procedural Outcomes: Restoration of Hemodynamics and Clinical Status
Following TTVR, the patient exhibited substantial symptomatic and functional improvement. Echocardiography demonstrated a stable reduction in TR, improved forward stroke volume, and favorable remodeling of the right atrium and ventricle. Clinically, dyspnea improved, exercise tolerance increased, and biomarkers of congestion normalized.
The durability of these improvements is critical. While TR reduction offers immediate symptomatic relief, long-term benefit depends on sustained RV compensation and stable PAH control. In this case, continued PAH therapy maintained favorable pulmonary hemodynamics, supporting RV function after the mechanical correction of regurgitation.
Notably, the case highlights that tricuspid repair did not exacerbate PAH or precipitate worsening RV function — a historically feared complication. Instead, the sequential strategy of medical optimization followed by intervention allowed the two therapies to complement one another.
From a mechanistic standpoint, reduced TR enhances forward output, lowers RA pressure, improves hepatic and renal congestion, and reduces systemic venous hypertension. These systemic effects produce a global improvement in organ function, explaining the broad clinical gains seen after TTVR.
Clinical Implications: Redefining the Therapeutic Strategy for TR in Severe PAH
This case challenges the traditional doctrine that significant TR in the setting of severe PAH is untreatable. Instead, it promotes a staged and individualized approach:
- optimize PAH therapy to reduce afterload,
- reassess RV–PA coupling via echo and catheterization,
- confirm mechanical reversibility of TR,
- consider TTVR only when RV contractility is sufficient to tolerate increased forward load.
This strategy is both physiologically sound and clinically validated by the outcomes of this case.
Historically, surgical repair in such patients carried prohibitive mortality. Transcatheter techniques, by contrast, offer a less invasive means of correcting regurgitation without imposing the stress of cardiopulmonary bypass. When combined with modern PAH therapies, previously contraindicated interventions may now become viable.
This evolving paradigm emphasizes the importance of dynamic reassessment. PAH is not static; neither should be the management of TR.
Conclusion
This case represents a landmark demonstration of how optimized PAH therapy can restore right ventricular function sufficiently to permit successful transcatheter tricuspid valve repair. Through careful hemodynamic assessment, staged therapeutic intervention, and expert procedural execution, the patient achieved significant and durable improvements in TR severity, pulmonary pressures, and overall functional capacity.
The lessons are clear:
- TR in PAH should not be automatically dismissed as irreversible.
- RV–PA coupling is modifiable with appropriate therapy.
- TTVR can be safe when applied selectively.
This case reinforces the need for collaborative, physiology-based decision-making and provides a roadmap for clinicians managing similarly complex patients.
FAQ
1. Why is severe TR traditionally considered untreatable in PAH?
Because surgical repair increases RV afterload dramatically, which decompensates an already failing ventricle. Historically, this led to high mortality. Modern PAH therapy and transcatheter approaches are changing this paradigm.
2. How does PAH therapy enable tricuspid repair?
By reducing pulmonary vascular resistance and restoring RV contractile reserve, thereby improving RV–PA coupling and allowing the heart to tolerate increased forward flow after TR reduction.
3. Is transcatheter tricuspid repair safe in PAH patients?
Not universally. It is safe only when preceded by demonstrated hemodynamic improvement under optimized PAH therapy. Proper patient selection is mandatory.
